Canada pauses AstraZeneca vaccine for under 55

The National Advisory Committee on Immunisation had recommended the pause for safety reasons and the Canadian Provinces, which administer health in the country, announced the suspension on March 29

Canada on March 29 suspended the use of the Oxford-AstraZeneca coronavirus vaccine for people under age 55 following concerns it might be linked to rare blood clots. The National Advisory Committee on Immunisation had recommended the pause for safety reasons and the Canadian Provinces, which administer health in the country, announced the suspension on Monday. “There is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccines to adults under 55 given the potential risks,” said Dr. Shelley Deeks, vice-chair of the National Advisory Committee on ImmuniSation.